Clinical management of patients receiving cell-based immunoregulatory therapy

Transfusion

Volumn 54, Issue 9, 2014, Pages 2336-2343

  Hutchinson, James A ^a   Ahrens, Norbert ^a   Riquelme, Paloma ^a   Walter, Lisa ^a   Gruber, Michael ^a   Böger, Carsten A ^a   Farkas, Stefan ^a   Scherer, Marcus N ^a   Broichhausen, Christiane ^a   Bein, Thomas ^a   Schlitt, Hans J ^a   Fändrich, Fred ^b   Banas, Bernhard ^a   Geissler, Edward K ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC REACTION; ARTICLE; BACTERIAL INFECTION; CELL FUNCTION; CELL ISOLATION; CELL THERAPY; CIRCULATORY OVERLOAD; DISEASE TRANSMISSION; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LUNG EMBOLISM; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); MYCOSIS; NONHUMAN; REGULATORY MACROPHAGE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSITIZATION; SHOCK; TRANSFUSION RELATED ACUTE LUNG INJURY; VIRUS INFECTION; GRAFT REJECTION; IMMUNOTHERAPY; PROCEDURES;

IMMUNOSUPPRESSIVE AGENT;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION;

EID: 84908206251     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12641     Document Type: Article

References (46)

1. Kilshaw PJ, Brent L, Pinto M. An active suppressor mechanism preventing skin allograft rejection in mice. Transplant Proc 1975;7:225-8.
2. Geissler EK, Hutchinson JA. Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients. Curr Opin Organ Transplant 2013;18: 408-15.
3. Tang Q, Bluestone JA, Kang SM. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol 2012;4:11-21.
4. Moreau A, Varey E, Bouchet-Delbos L, et al. Cell therapy using tolerogenic dendritic cells in transplantation. Transplant Res 2012;1:13.
5. Broichhausen C, Riquelme P, Geissler EK, et al. Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation. Curr Opin Organ Transplant 2012;17:332-42.
6. Bluestone JA, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol 2008;28:677-84.
7. Brem-Exner BG, Sattler C, Hutchinson JA, et al. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol 2008;180: 335-49.
8. Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol 2011;23:679-84.
9. Riquelme P, Geissler EK, Hutchinson JA. Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs. Transplant Res 2012;1:17.
10. Hutchinson JA, Riquelme P, Sawitzki B, et al. Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol 2011;187:2072-8.
11. Hutchinson JA, Riquelme P, Geissler EK. Human regulatory macrophages as a cell-based medicinal product. Curr Opin Organ Transplant 2012;17:48-54.
12. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptance-inducing cells as an immuneconditioning therapy in renal transplantation. Transpl Int 2008;21:728-41.
13. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cellbased approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008;21: 742-54.
14. Hutchinson JA, Roelen D, Riquelme P, et al. Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells. Transpl Int 2008;21:808-13.
15. Hutchinson JA, Govert F, Riquelme P, et al. Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible. Clin Transplant 2009;23:140-5.
16. Lopez F, Di BC, Piazza T, et al. A quality risk management model approach for cell therapy manufacturing. Risk Anal 2010;30:1857-71.
17. Gilliss BM, Looney MR, Gropper MA. Reducing noninfectious risks of blood transfusion. Anesthesiology 2011;115: 635-49.
18. Riquelme P, Tomiuk S, Kammler A, et al. IFN-gammainduced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther 2013;21: 409-22.
19. Smyth LA, Ratnasothy K, Moreau A, et al. Tolerogenic donor-derived dendritic cells risk sensitization in vivo owing to processing and presentation by recipient APCs. J Immunol 2013;190:4848-60.
20. Ahrens N, Pruss A, Kahne A, et al. Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion. Transfusion 2007;47:813-6.
21. MacLeod AM. The blood transfusion effect: clinical aspects. Immunol Lett 1991;29:123-6.
22. Eikmans M, Waanders MM, Roelen DL, et al. Differential effect of pretransplant blood transfusions on immune effector and regulatory compartments in HLA-sensitized and nonsensitized recipients. Transplantation 2010;90: 1192-9.
23. Anderson CB, Sicard GA, Etheredge EE. Pretreatment of renal allograft recipients with azathioprine and donorspecific blood products. Surgery 1982;92:315-21.
24. Ezzelarab MB, Zahorchak AF, Lu L, et al. Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant 2013;13:1989-2005.
25. Jawa RS, Young DH, Stothert JC, et al. Transfusionassociated graft versus host disease in the immunocompetent patient: an ongoing problem. J Intensive Care Med 2013 Jun 20. [Epub ahead of print]. doi: 10.1177/ 0885066613492645.
26. Hutchinson JA, Riquelme P, Geissler EK, et al. Human regulatory macrophages. Methods Mol Biol 2011;677:181-92.
27. Frey NV, Porter DL. GVHD after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol 2008;21:205-22.
28. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant 2008;42:569-79.
29. Hoffmann P, Boeld TJ, Eder R, et al. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 2009;39: 1088-97.
30. Schmidl C, Hansmann L, Andreesen R, et al. Epigenetic reprogramming of the RORC locus during in vitro expansion is a distinctive feature of human memory but not naive Treg. Eur J Immunol 2011;41:1491-8.
31. Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med 2011;17:673-5.
32. Hansmann L, Schmidl C, Kett J, et al. Dominant Th2 differentiation of human regulatory T cells upon loss of FOXP3 expression. J Immunol 2012;188:1275-82.
33. Tsuji M, Komatsu N, Kawamoto S, et al. Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches. Science 2009;323:1488-92.
34. Scotta C, Esposito M, Fazekasova H, et al. Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ T regulatory cell subpopulations. Haematologica 2013;98:1291-9.
35. Hogg JC, Doerschuk CM. Leukocyte traffic in the lung. Annu Rev Physiol 1995;57:97-114.
36. Doerschuk CM, Beyers N, Coxson HO, et al. Comparison of neutrophil and capillary diameters and their relation to neutrophil sequestration in the lung. J Appl Physiol 1993; 74:3040-5.
37. Kutscher HL, Chao P, Deshmukh M, et al. Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. J Control Release 2010;143: 31-7.
38. Hogg JC, Coxson HO, Brumwell ML, et al. Erythrocyte and polymorphonuclear cell transit time and concentration in human pulmonary capillaries. J Appl Physiol 1994;77:1795-800.
39. Mishkin FS, Brashear RE. Pulmonary and systemic blood pressure responses to large doses of albumin microspheres. J Nucl Med 1971;12:251-2.
40. Young I, Mazzone RW, Wagner PD. Identification of functional lung unit in the dog by graded vascular embolization. J Appl Physiol 1980;49:132-41.
41. Kauffman HM, Clark RF, Fisher LM, et al. Lethality of intravascular injections of spleen and liver cells. Ann Surg 1964; 159:227-43.
42. Kobayashi E, Hishikawa S, Teratani T, et al. The pig as a model for translational research: overview of porcine animal models at Jichi Medical University. Transplant Res 2012;1:8.
43. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723-37.
44. Schmidt D. Monocyte/macrophage system and malignancies. Med Pediatr Oncol 1994;23:444-51.
45. Heid JB, Schmidt A, Oberle N, et al. FOXP3+CD25-tumor cells with regulatory function in Sézary syndrome. J Invest Dermatol 2009;129:2875-85.
46. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev 2005;18:195-204.